Deborah Research will identify and move the most promising read-through molecule candidates into first-in-human clinical studies.
“we are currently evaluating, I think it's twenty, twenty five different, compounds, which resource from all different sources, from companies, from academia, from other, nonprofit organizations, which, have supported such therapies, for their disease, and which we evaluate again now in our dedicated CROs head to head in order to identify the most promising candidate or candidates, which we will then move forward into first, first in men, clinical studies.”
→ Read the source episode
Our resolution criterion
disputableAt least one read-through molecule candidate from Read On Therapeutics enters first-in-human clinical trials.
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Laurent Levy predicts Nanobiotics will complete pancreatic, melanoma, and esophageal cancer trials before H1 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.